The PREPARE for COVID Trial
PRomoting Exercise During the Pandemic to Increase Activity and Reduce Effects of Social Isolation for COVID: The PREPARE for COVID Trial
調査の概要
詳細な説明
Background:More than 6.5 million Canadians are > 65 years of age. Over half of older Canadians live with multiple comorbidities, leaving them at high risk of adverse outcomes of COVID-19. Social isolation and physical distancing orders are especially important to protect the health of this high-risk population. Vulnerable older Canadians are also at high risk of physical and mental health deterioration caused by the physical distancing meant to protect them from COVID-19. Effective management of the COVID-19 pandemic and its consequences will require evidence-based strategies to support isolated vulnerable older Canadians. Exercise interventions can reduce the adverse health effects of social isolation and demonstrate larger effect sizes in older people with comorbidities. However, no exercise interventions have been tested in an acute isolation scenario such as the COVID-19 pandemic, which also requires that exercise interventions be home-based and remotely supported, presenting unique challenges to participation and adherence.
Our team is uniquely positioned re-orient proven and robust programming, supported by a national network of investigators and existing infrastructure. We can immediately launch a large-scale trial to test the effectiveness of a remotely supported home exercise program (designed in partnership with vulnerable older Canadians) to mitigate the negative consequences of physical distancing to keep older Canadians healthy and safe from COVID-19. We hypothesize that participation in the PREPARE program will decrease the individual, health system and population health impacts of COVID19 induced physical distancing and social isolation.
Research aims:Estimate the effectiveness of a remotely supported, home-based multimodal exercise program for older people with multiple comorbidities to improve our primary outcome: patient-reported disability 90-days after enrollment; secondary outcomes: patient-centered (depression, anxiety, quality of life, frailty, survival, 1-year disability scores, COVID19 severity) and system-relevant (admissions, emergency visits, institutionalization, costs, cost-effectiveness).
Methods: Design, setting and participants: Parallel-arm multicenter randomized controlled trial at 3 Canadian hospitals. People >65 years old recently discharged home with >2 comorbidities will be included. Intervention: Three month supported home-based exercise program with demonstrated efficacy, feasibility and acceptability for vulnerable older people.
Outcomes and sample size: We will have 90% power to detect a clinically important difference of in our primary outcome (validated WHODAS tool, 90-days post-enrollment) with 372 participants (186/arm)
研究の種類
入学 (予想される)
段階
- 適用できない
連絡先と場所
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- 65 years of age or older
- 2 or more co-morbidities
- recent discharge from hospital
Exclusion Criteria:
- Inability to communicate in English or in French
- Unreachable by telephone
- Unstable cardiovascular or valvular disease
- Discharged to Long-Term Care
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：ヘルスサービス研究
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Exercise Group
The home-based exercise program called the PREPARE program. Exercise will be prescribed as one-hour sessions, performed a minimum of three times per week for at least three months, consisting of: 1) strength training; 2) aerobic exercise and 3) flexibility. |
A home-based exercise program guided by paper materials, weekly phone calls, and a DVD. Exercise will be prescribed as one-hour sessions, performed a minimum of three times per week for at least three months, consisting of: 1) strength training; 2) aerobic exercise and 3) flexibility. |
|
介入なし：対照群
対照群には、世界保健機関が推奨する65歳以上の人の身体活動に関するパンフレットと、高齢者向けの健康的な食事に関するガイドが与えられる。
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Patient-reported disability 90 days after enrollment
時間枠：Assessing change in score from baseline data collection to 90 days from enrollment
|
The World Health Organization Disability Assessment Schedule 2.0 (WHODAS) will be used .
It is a patient-reported disability scale that assesses limitations in six major life domains - cognition, mobility, self-care, social interaction, life activities and participation in society.
Participants will report if they have had no difficulty, mild difficulty, moderate difficulty, severe difficulty or extreme difficulty (simply cannot do) with the items listed.
|
Assessing change in score from baseline data collection to 90 days from enrollment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Mental Health
時間枠：Assessing change in the participants GAD-7 score from baseline to monthly scores for 12 months.
|
The Patient Health Questionnaire-9 item (PHQ-9) and the Generalized Anxiety Disorder 7-item (GAD-7) are validated tools for diagnosing anxiety and depression.
|
Assessing change in the participants GAD-7 score from baseline to monthly scores for 12 months.
|
|
Function
時間枠：Monthly step count from enrollment to monthly step counts for 12 months from enrollment.
|
Step count using pedometer
|
Monthly step count from enrollment to monthly step counts for 12 months from enrollment.
|
|
Health-related quality of life
時間枠：Assessing change in the participants EQ-5D-5L score from baseline to monthly scores for 12 months.
|
The EQ-5D-5L is a validated instrument with Canadian valuation statistics and national use, which informs incremental cost per quality-adjusted life year gained.
|
Assessing change in the participants EQ-5D-5L score from baseline to monthly scores for 12 months.
|
|
Frailty
時間枠：Assessing change in the participants CFS score from baseline to monthly scores for 12 months.
|
The Clinical Frailty Scale (CFS) provides a global assessment of frailty.
|
Assessing change in the participants CFS score from baseline to monthly scores for 12 months.
|
|
All-cause mortality.
時間枠：From enrollment to 12 months after enrollment.
|
All deaths and death dates will be identified via chart review or telephone call.
|
From enrollment to 12 months after enrollment.
|
|
Health System - Emergency Department Visits
時間枠：Monthly for 12 months following enrollment.
|
Monthly for 12 months following enrollment.
|
|
|
Health System - Re-admission
時間枠：Monthly for 12 months following enrollment.
|
Monthly for 12 months following enrollment.
|
|
|
Health System - Transfer to Long-Term Care
時間枠：Monthly for 12 months following enrollment.
|
Monthly for 12 months following enrollment.
|
|
|
COVID-19 test results
時間枠：Monthly for 12 months following enrollment.
|
Monthly for 12 months following enrollment.
|
|
|
Safety [Adverse Events]
時間枠：Assessing frequency of, or change in any safety events from enrollment up to 90 days from enrollment between the exercise group and control group.
|
Falls, cardiac or respiratory complications and unplanned healthcare encounters will be collected during the exercise treatment period for the exercise group.
For the control group, participants will be asked if they experienced any falls since the time of enrollment up until the day before surgery.
Unplanned healthcare encounters will also be collected during the time of enrollment to the final day of the exercise intervention for the intervention group through chart review.
|
Assessing frequency of, or change in any safety events from enrollment up to 90 days from enrollment between the exercise group and control group.
|
協力者と研究者
捜査官
- 主任研究者：Daniel I McIsaac, MD、The Ottawa Hospital Research Institute
研究記録日
主要日程の研究
研究開始 (予想される)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。